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Abstract 
In this study human myometrial tissues 
were examined for the presence of gap 
junctions by quantitative electron microscopy 
before and after incubation in tissue culture 
media with and without indomethacin. The 
area of gap junctions was very low in tissues 
from pregnant women at term but not labor, 
before incubation. After 24 and 48 h incuba- 
tion without any treatment, segments of some 
of the same tissues developed many gap junc- 
tions and other tissues contained few junc- 
tions. Prostaglandin E (PGE), prostaglandin F 
(PGF) and prostaglandin F metabolite (PGF 
metabolite) levels in the media at various 
times were measured by radioimmunoassay. 
The prostaglandins increased progressively 
during the incubation period. Treatment of 
tissues with indomethacin decreased prosta- 
glandin levels in the media and increased the 
numbers of gap junctions in those control 
tissues that developed few junctions over the 
same incubation interval. We conclude that 
the capacity of human myometrial tissues 
to develop gap junctions in vitro may depend 
upon a maturational stage in preparation for 
labor. Furthermore, our results suggest that 
products of the cycle-oxygenase or lipoxy- 
genase pathways may control the presence of 
gap junctions in the human myometrium and 
that changes in synthesis in these patterns 
may occur as part of the maturational process. 
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Introduction 
Gap junctions develop between muscle 
cells of the myometrium during term and 
preterm labor in various animals [ 6,11,17] 
and humans [ 111. The presence of the 
junctions correspond to the time when the 
myometrium is active and the occurrence of 
these cell-to-cell contacts is thought to be 
responsible for changing the myogenic proper- 
ties of the muscle cell such that electrical 
events propagate between cells to synchronize 
contractility [ 181. If gap junctions are 
necessary for labor then an understanding of 
the conditions which either stimulate or 
inhibit their presence is of considerable 
clinical significance. 
The mechanisms which promote the exist- 
ence of myometrial gap junctions is not 
completely understood. In animals, changes in 
the levels of steroid hormones and prosta- 
glandins, which precede and accompany 
labor, are thought to control the synthesis 
and enlargement of the junctions [ 7- 10,111. 
In the human myometrium there is no evi- 
dence for these regulatory mechanisms and 
the steroid hormone changes which take 
place before and during labor are not as 
distinct as those of most animals [2]. How- 
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ever, in all species including humans increased 
synthesis and release of prostaglandins are 
apparent and these compounds appear to be 
involved in the onset and progression of labor 
[ 1,2,5]. There is also evidence that prosta- 
glandins interact with the steroid hormones 
to regulate gap junctions in the rat uterus 
[ 141. However, there are conflicting reports 
as indomethacin treatment appears to inhibit 
gap junctions in some circumstances [8] and 
stimulate their presence in others [ 141. It is 
possible that the prostaglandins are the 
primary control mechanism for gap junction 
formation in the human uterus. 
Studies of some treatments which may 
prevent or initiate gap junctions are not 
possible in humans. However, previous 
studies with animal tissues have shown that 
gap junctions develop spontaneously in vitro 
and this model system has been used to 
investigate agents which either promote or 
inhibit the formation of junctions [ 7,8]. In 
the present study, we quantitated the num- 
bers of gap junctions in myometrial tissues 
from women not in labor before and with 
and without treatment with indomethacin. 
Our study shows that the gap junctions 
develop slowly in vitro and the results 
indicate that a product(s) of the cycle 
oxygenase or lipogenase pathway may control 
the presence of the junctions. 
Materials and methods 
The methods used in this study were 
similar to those used previously for animal 
[ 7,8 ] and human tissues [ 111. 
Tissues 
Uterine tissues (approx. 3 X 2 X 1 cm) 
were excised from the lower uterine segments 
of the cesarean openings from 12 women 
undergoing elective operations. The average 
gestation age was 39 weeks with a range of 
dates from 36 to 41 weeks. None of the 
patients was in active labor. Informed consent 
to remove the tissue and participate in the 
study was obtained from each woman by 
the attending physician. This project was 
approved by the Ethics Committees of the 
authors’ institutions. 
Immediately after removal the tissues were 
placed in ice-cold Krebs-Ringer’s solution and 
within 20 min divided into pieces (approx. 
1 cm X 1 mm X 0.5 mm) with the muscle 
oriented in the long axis. Each piece was 
stretched 1.5 times the excised length with 
stainless steel pins. Some tissues were then 
fixed for electron microscopy (control = zero 
time). Other tissues from the same uterine 
segment were fixed after incubation in a CO* 
incubator at 37’C for various times and 
treatments. The incubation media used was 
MEM (Minimum Essential Medium, Gibco) 
without fetal calf serum. Samples of the 
media were collected at selected times and 
analyzed for prostaglandins. Indomethacin 
(Merck Frosst Laboratories) was dissolved 
in 1% sodium carbonate and added to the 
culture media in 10 ~1 volumes. The same 
volume of sodium carbonate was also added 
to media containing control tissues. 
Electron microscopy 
All tissues were fixed by immersion in 
buffered 2% glutaraldehyde solution and pre- 
pared for electron microscopy as described 
previously [ 6- 111. The tissues were examined 
and photographed (approx. 40 photos/tissue) 
in a Philips Model 301 electron microscope. 
The lengths of the gap junctions and non- 
junctional membranes were determined in the 
photographs by the methods used formerly 
1111. 
Prostaglandin analysis 
The procedures for prostaglandin measure- 
ments have also been published previously 
[ 12,131 with only minor changes for this 
study. No extraction or column chromato- 
graphy was performed for analysis of the 
samples of tissue culture media. Briefly, the 
media samples (1 ml) were placed in polypro 
pylene tubes (Falcon, Oxnard, CA) containing 
enough indomethacin to give a final concen- 
tration of at least 10 pg/ml and centrifuged at 
500 X g for 20 min. The supematants were 
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placed in capped tubes and stored at -20°C 
until assay. The frozen media were then 
thawed and assayed directly without extrac- 
tion or chromatography. Two lOO-~1 aliquots 
were used for each assay of PGF, PGE and 
13,14-dihydro-15-keto PGF (PGF metabolite). 
To each Biovial@ (Beckman Instruments, 
Fullerton, CA) was added 100 ~1 sample, 
200 ~1 of phosphate buffered saline contain- 
ing 0.3% bovine gamma globulin (Miles 
Laboratories, Inc., Elkhart, IN) and 5500 cpm 
of the appropriate labelled PG - [5,6,8,9,11, 
12,14,15(n)-3H]PGF, (178 Ci/mmol), [5,6,8, 
11,12,14,15(n)-3Hl PGEz (178 Ci/mmol) or 
[5,6,8,9,11,12,14(n)-3H] 13,lCdihydro-15- 
keto PGFz (80 Ci/mmol) (Amersham Corp., 
Arlington Heights, IL) - diluted in 100 ~1 of 
the same buffer. The tubes were vortexed and 
100 ~1 of the appropriate antibody added. 
The antibodies were obtained from Seragen, 
Boston, MA (anti PGF2, batch No. 212205, 
dilution 1:35000: anti PGEz, batch No. 
301132, dilution 1: 14000) or Dr. K. Kirton, 
Upjohn Co., Kalamazoo, MI (anti PGF meta- 
bolite, batch No. 11560-JCC-14OD, 80 mg/ml 
diluted 1 : 25000 for assay). The cross- 
reactions of these antibodies were as follows. 
Anti PGF2: PGF2, PGF, - 100%; PGE1, 
6-keto PGF, - l-1 % and all others less than 
0.5%. Anti PGEz: PGE*, PGEl - 100%; 
PGA, - 6%; PGAl - 3%; 6-keto PGEi - 1%; 
PGF, - 1.3% and all others less than 1%. Anti 
PGF metabolite: 13,14-dihydro-15-keto 
PGF, - 100%; 15-keto* - 20%; C-16 urinary 
metabolites of Fz < 1%; 13,14dihydro 
PGFz -<0.5% and PGFz - 0.1%. This 1st 
antibody was very kindly provided by Dr. 
K.T. Kirton of the Upjohn Co. and the data 
regarding cross-reactions are taken from a 
personal communication from him. 
After addition of the antibody, the tubes 
were incubated for 4 h at 4°C and 0.5 ml of 
65% polyethylene glycol (Sigma Chemical 
Co., St. Louis, MO) in distilled water contain- 
ing 2 mM CaCl? at pH 7.4 was added and 
vortexed. The tubes were centrifuged at 
20 000 X g for 30 min at 4°C. After removal 
of the supernatant, 0.2 ml of 0.1 N NaOH 
was added to dissolve the pellet, the sample 
vortexed and 3.5 ml of scintillation cocktail 
(24 g PPO, 1.2 g POPOP in 3600 ml of 
toluene and 400 ml Biosolv@ BBS-3) were 
added. Biosolv, PPO, POPOP were purchased 
from Beckman Co. The samples were counted 
in a Beckman LS 330 liquid scintillation 
spectrometer with an efficiency for 3H of 
40%. Non-specific binding was always less 
than 5%. Appropriate blank and known stan- 
dards were run in each assay. The values for 
media alone never exceeded 2 pg/tube in any 
of the three assays. 
Statistical analysis 
The paired Student’s t-test was used to 
compare differences between control tissues 
and segments of the same tissues after treat- 
ments. A P value of 0.05 or less was consi- 
dered significant. 
RWlltS 
Time course of gap junction development 
Electron micrographs of myometrial gap 
junctions at high and low magnification are 
shown in Figs. 1 and 2. Figure 3 shows the 
gap junction area in tissues from 8 women 
before and following incubation for up to* 
48 h. All tissues contained very few gap junc- 
tions before incubation. Tissues from 3 
women (MC, ET, and RD) progressively 
developed more junctions and contained 
very high values after 48 h. There was little 
gap junction development in tissues from 
5 women (VW, KB, MB, LO and VS) over 
the 48-h incubation period. Tissue from one 
postdated woman (41 weeks, VS) contained 
the lowest area of junctions after 48 h in 
vitro. 
Effects of indomethacin 
The gap junction area, in segments of the 
same tissues used in the control experiments 
(Fig. 3) but treated with indomethacin 
(20 &ml), at various times of incubation is 
shown in Figure 4. All tissues, except one 
(ET), contained gap junction areas above 
0.2% after 48 h incubation. 
Comparison of the gap junction areas in 
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Figs. 1,2. Electron micrographs of myometrial tissues after 48 h incubation showing gap junctions between muscle cells at inter- 
mediate (Fig. 1, X 64,000) and high magnification (Fig. 2, X 118,000). 
control and indomethacin-treated (20 pdrnl) 
tissues at 48 h is shown in Fig. 5. There was 
no significant difference (P > 0.05) between 
the mean control junction area values (0.33 + 
0.34% S.E.M.) and the mean values from all 
the indomethacin-treated tissues (0.45 + 
0.21%). However, indomethacin resulted in a 
significant increase (P < 0.05) in all 5 tissues 
from women (KB, VS, MB, VW, LD) in which 
the control tissues developed very few junc- 
tions over 48 h (i.e. below 0.2%). Indometha- 
tin reduced, but not to significant levels, the 
gap junction area in 3 tissues from the 3 
women (MC, RD, ET) where the control tissues 
had many junctions at 48 h. 
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Prostaglandins in the media 
The levels of prostaglandins E(PGE), 
F(PGF) and 13,14-dihydro-15-keto-PGF 
(PGF metabolite) in media collected at 
various times from dishes containing the 
control and indomethacin (20 pglml) treated 
tissues is shown in Figs. 6, 7 and 8. The 
amounts (normalized to g of tissue wet 
weight) of PGE, PGF and PGF metabolite in 
the media surrounding control tissues in- 
creased progressively with time. At 48 h there 
was about 3 times as much PGE in the media 
as PGF. Also, at 48 h there was approxi- 
mately 4 times as much PGF as PGF meta- 
bolite. The levels of PGE and PGF were 
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Fig, 3. Gap junction area, as 7% of plasma membrane area, in 
control tissues from 8 women at 0 h and at various times up 
to 48 h incubation. 
significantly (I’ < 0.05) reduced at all times 
by indomethacin. However, indomethacin 
did not prevent the initial rise in PGF meta- 
bolite. 
12 24 35 45 
HOUNS OF lNCMATlON 
Fig. 4. Gap junction area during 48 h incubation with indo 
methacin (20 &ml) from tissues of the same women shown 
in Fig. 3. 
CONTROL INDOYElHACIN 
MEANS+S.D. !! 
0.33=0.34 All DNIN 0.45t0.21 N.S. 
0.10=0.00 Low bntmla 0.52r0.15 co.002 
0.71=0.23 HI@ contml* 0.35~0.27 N.S. 
Fig. 5. Comparison of the gap junction area after 48 h 
incubation in the control and indomethacin-treated tissues. 
Note that there were no significant differences (P < 0.05) 
between control and indomethacin gap junction values when 
all data was considered. However, tissues from 5 women 
(KB, VS, MB, VW, LD) with low gap junction areas (i.e. 
below 0.2%), contained significantly (P < 0.002) higher 
gap junction areas after treatment with indomethacin. Tissues 
from 3 women (MC, RD, ET) with high control values con- 
tained less after incubation with indomethacin but the mean 
values were not significantly different (P > 0.05). 
Discussion 
This study shows that myometrial gap 
junctions develop slowly in some of the 
tissues in vitro. Tissues removed from women 
prior to labor contained very few gap junc- 
tions but segments of some of the same 
tissues contained more after incubation. 
These results are similar to those seen in 
animal tissues studied in vitro [7,8]. How- 
ever, it is obvious that tissues from other 
women had less capacity to form gap junc- 
tions. These results can perhaps be explained 
on the basis that the development and 
presence of gap junctions in vitro or in vivo 
is the result of maturational events in prepara- 
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Fig. 6. Levels of prostaglandin E (ng PGE/g myometrial 
per ml of MEM) in the incubation media bathing tissues in 
the absence (control) and presence of indomethacin (20 rgl 
ml). Points are mean values i S.E.M. from 4 separate tissues. 
tion for labor and that the tissues used in this 
study were from women at different stages of 
that maturational process. 
It should be noted that any change in gap 
junctions could be the result of changes in 
their synthesis and/or degradation. It is 
loo- pGF 
w _ - CONTROL 
60- 
----- INDOMETHACIN (20 (rglml) 
70 - 
1 STANDARD ERROR 
60- 
!50- 
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Fig. 7. Levels of prostaglandin F (PGF) in the incubation 
media from control and indomethacti-treated tissues. Data 
as shown in Fig. 6. 
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Fig, 8. Levels of 13,14_dihydro-15-keto prostaglandin F 
(PGF metabolite) in the bathing media from control and 
indomethacin-treated tissues. Data as shown in Fig. 6. 
obvious from the present study that tissues 
which develop large numbers of junctions 
in vitro, either spontaneously or after indo- 
methacin treatment, do so over an extended 
period (i.e. 24-48 h, see Figs. 3 and 4). 
This time period may be equivalent to the 
time required in vivo for the presence 
of sufficient junctions for labor to progress. 
We assume that the presence of the junctions 
is the result of increased synthesis as is 
thought to be the case for myometrial tissues 
from animals [ 101. 
It is obvious that the presence of the 
placenta, decidua, fetal membranes and 
fetus are not necessary for gap junctions to 
form in vitro as our tissue specimens were 
primarily muscle. However, these tissues may 
modulate the presence of the junctions 
through the production of prostaglandins and 
other regulatory molecules or mediate the 
action of the steroid hormones [see 191. 
Our results show that the tissues released 
PGE, PGF and PGF metabolite into the 
incubation media (Figs. 6-8) and that the 
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amounts of prostaglandins were reduced 
significantly by indomethacin treatment. 
These results are in agreement with reports 
by others [ 3,4] . Similarly our study shows 
that more PGE is produced than PGF which 
corresponds with prior observations [ 191. 
However, the prostanoids we measured in 
this study may not be the ones involved in 
regulation of the junctions. 
Previously we have found in human and 
animal tissues that labor and delivery occurred 
when approximately 0.2-0.3% of the plasma 
membrane of myometrial cells was occupied 
by gap junctions [ 11,171. In this study we 
show that indomethacin increases gap junc- 
tion area in segments of those same tissues 
which developed less than 0.2% of membrane 
area in control incubations (Fig. 5). This may 
mean that a product of the cyclooxygenase 
pathway prevents gap junction development 
and that a shift in the synthesis of the cyclo- 
oxygenase inhibitory product is one of the 
steps involved in the maturational process 
in preparation for labor. Our previous studies 
suggest that prostacyclin (PG12), a cyclooxy- 
genase product, may inhibit the presence of 
myometrial gap junctions [81. Other studies 
in animals also show that indomethacin and 
meclofenamate treatment increase gap junc- 
tion area [ 141. These results support the 
notion that PG12 prevents gap junction 
development. The concept that a change in 
the synthesis from PGIz to other prostanoids 
may be part of the maturational events prior 
to labor has been proposed [ 1,161. Another 
possibility to explain the above results is that 
products of the lipogenase pathway regulate 
(stimulate) the presence of the junctions 
and that when the activity of the cycloxygen- 
ase enzyme is inhibited with indomethacin, 
arachidonic metabolism is shifted to the 
lipoxygenase pathway and production of 
leukotrienes. 
In contrast, indome thacin consistently 
prevented an increase in gap junctions in 
tissues in which control pieces of the same 
tissues developed many junctions (Fig. 5). 
These results may indicate that more than one 
Myometrial &up junctions 247 
prostanoid is involved in either controlling 
the synthesis or degradation of the junctions. 
Another possibility is that the presence of 
myometrial gap junctions is controlled by a 
balance between production from the cyclo- 
oxygenase and lipoxygenase pathways. The 
differences observed in the ability of indo- 
methacin to induce gap junctions in some 
tissues and prevent their appearance in others 
is also supported by previous studies. Indo- 
methacin inhibits gap junctions in rat myo- 
metrial tissues in vitro (i.e. in tissues which 
develop many junctions in vitro [8]), and the 
drug stimulates gap junctions in myometrial 
tissues in animals treated with indomethacin 
plus estradiol in vivo [ 14,151. 
Our study has important implications in 
the management of labor. Inhibition of 
prostaglandin synthesis may stimulate the 
presence of gap junctions in some patients 
as well as decrease the synthesis of products 
which may directly accelerate and augment 
contractility. Further studies are needed to 
define fully the mechanisms involved in the 
control of myometrial gap junctions and their 
involvement in labor. 
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